image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 4.6
2.68 %
$ 1.64 B
Market Cap
65.71
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GDRX stock under the worst case scenario is HIDDEN Compared to the current market price of 4.6 USD, GoodRx Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GDRX stock under the base case scenario is HIDDEN Compared to the current market price of 4.6 USD, GoodRx Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GDRX stock under the best case scenario is HIDDEN Compared to the current market price of 4.6 USD, GoodRx Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GDRX

image
$5.2$5.2$5.0$5.0$4.8$4.8$4.6$4.6$4.4$4.4$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
792 M REVENUE
5.61%
65.8 M OPERATING INCOME
343.81%
16.4 M NET INCOME
284.82%
184 M OPERATING CASH FLOW
32.97%
-70.3 M INVESTING CASH FLOW
-26.15%
-337 M FINANCING CASH FLOW
-101.62%
203 M REVENUE
2.21%
23.4 M OPERATING INCOME
28.60%
11.1 M NET INCOME
63.98%
9.41 M OPERATING CASH FLOW
-78.96%
-51.9 M INVESTING CASH FLOW
-211.68%
-105 M FINANCING CASH FLOW
-2871.73%
Balance Sheet GoodRx Holdings, Inc.
image
Current Assets 659 M
Cash & Short-Term Investments 448 M
Receivables 161 M
Other Current Assets 50.1 M
Non-Current Assets 729 M
Long-Term Investments 0
PP&E 40.5 M
Other Non-Current Assets 688 M
32.30 %11.59 %3.61 %2.91 %49.59 %Total Assets$1.4b
Current Liabilities 124 M
Accounts Payable 14.1 M
Short-Term Debt 10.6 M
Other Current Liabilities 99.1 M
Non-Current Liabilities 540 M
Long-Term Debt 533 M
Other Non-Current Liabilities 6.76 M
14.94 %80.31 %Total Liabilities$663.4m
EFFICIENCY
Earnings Waterfall GoodRx Holdings, Inc.
image
Revenue 792 M
Cost Of Revenue 48.2 M
Gross Profit 744 M
Operating Expenses 678 M
Operating Income 65.8 M
Other Expenses 49.5 M
Net Income 16.4 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00792m(48m)744m(678m)66m(49m)16mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
93.91% GROSS MARGIN
93.91%
8.31% OPERATING MARGIN
8.31%
2.07% NET MARGIN
2.07%
2.26% ROE
2.26%
1.18% ROA
1.18%
2.69% ROIC
2.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GoodRx Holdings, Inc.
image
160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020192019202020202021202120222022202320232024202420252025
Net Income 16.4 M
Depreciation & Amortization 69.5 M
Capital Expenditures -70.3 M
Stock-Based Compensation 99 M
Change in Working Capital 2.09 M
Others 108 M
Free Cash Flow 114 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GoodRx Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for GDRX of $9.5 , with forecasts ranging from a low of $9 to a high of $10 .
GDRX Lowest Price Target Wall Street Target
9 USD 95.65%
GDRX Average Price Target Wall Street Target
9.5 USD 106.52%
GDRX Highest Price Target Wall Street Target
10 USD 117.39%
Price
Max Price Target
Min Price Target
Average Price Target
101099887766554433Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership GoodRx Holdings, Inc.
image
Sold
0-3 MONTHS
15.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
565 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription service for erectile dysfunction (ED). Designed to meet consumers where they are and remove common barriers such as high costs, long wait times, and inconvenience, this all-in-one solution offers a fast, discreet, and affordable option for ED treatment. A new report from GoodRx reveals a clear gap in care: nearly 1 in 3 U.S. men. businesswire.com - 3 weeks ago
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the industry challenges that independent community pharmacies face around complex reimbursement models and competitive pressures, Community Link leverages a cost-plus pricing model based on NADAC to provide predictable pricing and favorable economics. This announcement showcases GoodRx's commitment to help. businesswire.com - 3 weeks ago
GoodRx: Stabilizing Revenue Amid Healthy Profit Gains I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma partnerships, and robust EBITDA margins support the investment thesis for a rebound. Despite risks like Rite Aid's bankruptcy and flat consumer growth, GoodRx's direct pharma channel is growing double digits and offsetting headwinds. seekingalpha.com - 4 weeks ago
GoodRx to Launch Direct Contracting for Independent Community Pharmacies SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide indep. businesswire.com - 1 month ago
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company's first-quarter earnings. benzinga.com - 1 month ago
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX. zacks.com - 1 month ago
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors? zacks.com - 1 month ago
GoodRx Holdings, Inc. (GDRX) Q1 2025 Earnings Call Transcript GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Aubrey Reynolds – Director-Investor Relations Wendy Barnes – President and Chief Executive Officer Chris McGinnis – Chief Financial Officer Conference Call Participants Lisa Gill – JPMorgan John Ransom – RJF Charles Rhyee – TD Cowen Jailendra Singh – Truist Securities Craig Hettenbach – Morgan Stanley George Hill – Deutsche Bank Steven Valiquette – Mizuho Securities Allen Lutz – Bank of America Michael Cherny – Leerink Partners Daniel Grosslight – Citi Operator Ladies and gentlemen, thank you for standing by and welcome to the GoodRx First Quarter 2025 Earnings Call. As a reminder, today's conference is being recorded. seekingalpha.com - 1 month ago
Is GoodRx (GDRX) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago. zacks.com - 1 month ago
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth GoodRx (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
8. Profile Summary

GoodRx Holdings, Inc. GDRX

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.64 B
Dividend Yield 0.00%
Description GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Contact 2701 Olympic Boulevard, Santa Monica, CA, 90404 https://www.goodrx.com
IPO Date Sept. 23, 2020
Employees 738
Officers Ms. Vina M. Leite Chief People Officer Mr. Ryan Sullivan Chief Marketing Officer Mr. Christopher A. McGinnis Chief Financial Officer & Treasurer Ms. Aubrey Reynolds Director of Investor Relations Mr. Trevor Bezdek Co-founder & Co-Chairman of the Board Ms. Wendy Barnes President, Chief Executive Officer & Director Mr. Romin Nabiey Chief Accounting Officer Mr. Douglas Joseph Hirsch Co-founder & Director Mr. Nitin Shingate Chief Technology Officer Ms. Gracye Cheng Senior Vice President, General Counsel & Secretary